// App-Quantinova.ai

BSH2020‐PO‐099 : Incidence of BTK mutations in chronic lymphocytic leukaemia treated with BTK inhibitors in a single UK institution

Researchers

Presenter

  • E. Santambrogio

Principal Investigators

  • T. Munir

  • A. C. Rawstron

  • P. Evans

  • P. Webster

  • P. Hillmen

Medical Centers

  • Medical Oncology, Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Italy

  • Haematology, St James's University Hospital, Leeds

  • Haematological Malignancy Diagnostic Service, St James's University Hospital

  • Leeds Teaching Hospital Trust, Leeds, UK

Locations

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • Bruton tyrosine kinase

  • Phospholipase C-gamma-2

  • Immunoglobulin heavy-chain variable region gene

Drug/Treatment

  • ACP-196

  • Tirabrutinib

  • Venetoclax

  • Ibrutinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved